Bullish & Foolish
Full BBLG fundamentals All 466 on the Survival Watch

BBLGBone Biologics Corporation

Is Bone Biologics struggling financially?

Yes, by its own account. Bone Biologics told the SEC on 14 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

28/100

Fragile

Sector
Biotech/Pharma
Market cap
$1.7M
Source filing
10-Q 14 May 2026
Balance sheet
30 Jun 2026

Cash runway

Not estimable

The latest filings do not carry the cash or cash-flow lines needed to estimate a runway. Publishing a number here would mean inventing one.

What it reported

Cash burned over the last 12 months

$4.8M

What Bone Biologics told the SEC

…a net loss of $ 0.8 million and used net cash in operating activities of $ 0.8 million during the three months ended March 31, 2026. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. In addition, our independent registered public accounting firm, in their audit report to the financial…

Bone Biologics Corporation, Form 10-Q, filed 14 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 230.0% share-count increase The company issued stock. Each share now owns 69.7% less of the business than a year ago, before any change in the price.
  • Cash burn is narrowing It is spending 25% less cash per year than it was, so the runway above is lengthening rather than shortening.

Other Biotech/Pharma companies that filed the doubt